Advertisement

Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma

  • Mario MandalàEmail author
  • Daniela Massi
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 249)

Abstract

The therapy of metastatic melanoma (MM) was radically changed by the introduction of inhibitors of BRAF, an oncogene mutated in ≈40–50% of patients. Oncogenic BRAF promotes an immune-compromised tumour microenvironment (TME). Inhibition of MAPK pathway signaling with BRAF (BRAFi) and MEK inhibitors (MEKi) attenuates immune escape and increases the melanoma immunogenicity through multiple mechanisms, including elevation of melanoma antigen expression and improved T cell infiltration and function. These changes sustain the TME for response to immunotherapy. In this chapter we discuss preclinical and clinical data supporting the immunomodulating activities of targeted therapies, the immunotolerance as a mechanisms of resistance and highlight the rationale for novel combinations of targeted therapies and immunotherapies with the potential to significantly improve the future treatment of MM patients.

Keywords

BRAF BRAF inhibitors Immunotolerance MEK inhibitors Resistance 

References

  1. Biechele TL, Kulikauskas RM, Toroni RA et al (2012) Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal 5(206):ra3PubMedPubMedCentralGoogle Scholar
  2. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516CrossRefGoogle Scholar
  3. Das Thakur M, Salangsang F, Landman AS et al (2013) Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494(7436):251–255CrossRefGoogle Scholar
  4. Falchook GS, Long GV, Kurzrock R et al (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379(9829):1893–1901CrossRefGoogle Scholar
  5. Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363(9):809–819CrossRefGoogle Scholar
  6. Flaherty KT, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2):107–114CrossRefGoogle Scholar
  7. Frederick DT, Piris A, Cogdill AP et al (2013) BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 19(5):1225–1231CrossRefGoogle Scholar
  8. Gray-Schopfer VC, Karasarides M, Hayward R, Marais R (2007) Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Res 67(1):122–129. Erratum in: Cancer Res. 2007; 67(4):1877CrossRefGoogle Scholar
  9. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70CrossRefGoogle Scholar
  10. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674CrossRefGoogle Scholar
  11. Haq R, Yokoyama S, Hawryluk EB et al (2013) BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A 110(11):4321–4326CrossRefGoogle Scholar
  12. Hauschild A, Grob JJ, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358–365CrossRefGoogle Scholar
  13. Hugo W, Shi H, Sun L et al (2015) Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 162(6):1271–1285CrossRefGoogle Scholar
  14. Hu-Lieskovan S, Mok S, Homet Moreno B et al (2015) Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med 7(279):279ra41CrossRefGoogle Scholar
  15. Johannessen CM, Boehm JS, Kim SY et al (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468(7326):968–972CrossRefGoogle Scholar
  16. Johansen LL, Lock-Andersen J, Hviid TV (2016) The pathophysiological impact of HLA class Ia and HLA-G expression and regulatory T cells in malignant melanoma: a review. J Immunol Res 2016:6829283CrossRefGoogle Scholar
  17. Khalili JS, Liu S, Rodríguez-Cruz TG et al (2012) Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 18(19):5329–5340CrossRefGoogle Scholar
  18. Larkin J, Ascierto PA, Dréno B et al (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371(20):1867–1876CrossRefGoogle Scholar
  19. Long GV, Stroyakovskiy D, Gogas H et al (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386(9992):444–451CrossRefGoogle Scholar
  20. Mandalà M, De Logu F, Merelli B, Nassini R, Massi D (2016) Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation. Lab Investig. doi: 10.1038/labinvest.2016.132. [Epub ahead of print]CrossRefPubMedGoogle Scholar
  21. Massi D, Brusa D, Merelli B et al (2014) PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann Oncol 25(12):2433–2442CrossRefGoogle Scholar
  22. Massi D, Brusa D, Merelli B et al (2015) The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. Ann Oncol 26(9):1980–1987CrossRefGoogle Scholar
  23. Menzies AM, Long GV (2014) Systemic treatment for BRAF-mutant melanoma: where do we go next? Lancet Oncol 15(9):e371–e381CrossRefGoogle Scholar
  24. Merelli B, Massi D, Cattaneo L, Mandalà M (2014) Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol 89(1):140–165CrossRefGoogle Scholar
  25. Ribas A, Hamid O, Daud A et al (2016) Association of Pembrolizumab with Tumor Response and Survival Among Patients with Advanced Melanoma. JAMA 315(15):1600–1609. Erratum in: JAMA 2016 Jun 14;315(22):2472CrossRefGoogle Scholar
  26. Robert C, Karaszewska B, Schachter J et al (2015a) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372(1):30–39CrossRefGoogle Scholar
  27. Robert C, Schachter J, Long GV et al (2015b) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521–2532CrossRefGoogle Scholar
  28. Schadendorf D, Hodi FS, Robert C et al (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33(17):1889–1894CrossRefGoogle Scholar
  29. Smith MP, Sanchez-Laorden B, O'Brien K et al (2014) The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα. Cancer Discov 4(10):1214–1229CrossRefGoogle Scholar
  30. Smyth MJ, Ngiow SF, Ribas A, Teng MW (2016) Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 13(3):143–158CrossRefGoogle Scholar
  31. Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366(8):707–714CrossRefGoogle Scholar
  32. Spranger S, Bao R, Gajewski TF (2015) Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523(7559):231–235CrossRefGoogle Scholar
  33. Straussman R, Morikawa T, Shee K et al (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487(7408):500–504CrossRefGoogle Scholar
  34. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y (2006) The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203(7):1651–1656CrossRefGoogle Scholar
  35. Teng MW, Ngiow SF, Ribas A, Smyth MJ (2015) Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 75(11):2139–2145CrossRefGoogle Scholar
  36. Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568–571CrossRefGoogle Scholar
  37. Wargo JA, Cooper ZA, Flaherty KT (2014) Universes collide: combining immunotherapy with targeted therapy for cancer. Cancer Discov 4(12):1377–1386CrossRefGoogle Scholar
  38. Wilmott JS, Long GV, Howle JR et al (2012) Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 18(5):1386–1394CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Unit of Medical Oncology, Department of Oncology and HaematologyPapa Giovanni XXIII Cancer Center HospitalBergamoItaly
  2. 2.Division of Pathological Anatomy, Department of Surgery and Translational MedicineUniversity of FlorenceFlorenceItaly

Personalised recommendations